Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
RO7017773 Phase I · 1 trial · 1 indication
Taste was assessed using a questionnaire that asking participants to rate the overall taste of study drug dispersed in various vehicles on a scale from 1-5, with 1=no taste, and 5=very intense taste.
| Arm | Type | Description |
|---|---|---|
| Part 1 | EXPERIMENTAL | Participants will receive 4 single oral doses of RO7017773 under either fed or fasted conditions, one of which will be a taste assessment. There will be a 7-10 day washout period between doses. |
| Part 2 | EXPERIMENTAL | Participants will receive 2 single oral doses of RO7017773, either sweetened/flavored, or unflavored and dispersed in juice. There will be a 7-10 day washout period between doses. |
| Name | Type | Description |
|---|---|---|
| RO7017773 Phase I Capsule | DRUG | Participants will receive 1 single oral dose of RO7017773 Phase I Capsule. |
| RO7017773 Phase II Tablet Unflavored | DRUG | Participants will receive 3 single oral doses of unflavored RO7017773 Phase II tablet during Part 1, and 1 single oral dose of unflavored RO7017773 Phase II tablet during Part 2. |
| RO7017773 Phase II Tablet Sweetened/Flavored | DRUG | Participants will receive 1 single oral dose of sweetened/flavored RO7017773 Phase II tablet during Part 2. |
Inclusion Criteria * Non-smoker for at least six months * Healthy, as judged by the Investigator * Women of non-childbearing potential (WONCBP) who are not pregnant or lactating * Men must be willing to remain abstinent or agree to use contraceptive measures with partners who are women of childbear...
RO7017773 Phase I is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is in early clinical development. The completed Phase 1 trial assessed the relative bioavailability of tablet versus capsule formulations, the effect of food, and taste assessment of the tablet formulation in healthy participants.
RO7017773 Phase I is being developed by Roche Holding AG, traded on the OTC market under the ticker RHHBY. The company conducted a Phase 1 clinical trial of this investigational small molecule in healthy volunteers in the United States.
RO7017773 Phase I is in Phase 1 clinical development. It is an investigational drug, not approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently ongoing for this asset.
RO7017773 Phase I has one completed clinical trial, NCT03847987. This was a two-part study in healthy participants to assess the relative bioavailability of tablet versus capsule formulations, the effect of food, and taste assessment of the tablet formulation. The trial enrolled 24 participants in the United States.
RO7017773 Phase I refers to the same investigational drug, RO7017773, which is currently in Phase 1 clinical development. The name includes the phase to distinguish the development stage, but the compound is identical. It is being studied in healthy volunteers for formulation assessment.